Literature DB >> 28322259

Incontinence: How do β3-adrenoceptor agonists work in the bladder?

Yasuhiko Igawa1, Naoki Aizawa1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28322259     DOI： 10.1038/nrurol.2017.43

Source DB:  PubMed          Journal:  Nat Rev Urol        ISSN： 1759-4812            Impact factor:   14.432


× No keyword cloud information.
  10 in total

1.  Urodynamics and safety of the β₃-adrenoceptor agonist mirabegron in males with lower urinary tract symptoms and bladder outlet obstruction.

Authors:  Victor W Nitti; Steven Rosenberg; David H Mitcheson; Weizhong He; Allam Fakhoury; Nancy E Martin
Journal:  J Urol       Date:  2013-05-30       Impact factor: 7.450

2.  Beta-3 adrenergic receptor is expressed in acetylcholine-containing nerve fibers of the human urinary bladder: An immunohistochemical study.

Authors:  Ana Coelho; Tiago Antunes-Lopes; James Gillespie; Francisco Cruz
Journal:  Neurourol Urodyn       Date:  2017-02-10       Impact factor: 2.696

Review 3.  Physiological and pathophysiological implications of micromotion activity in urinary bladder function.

Authors:  B Vahabi; M J Drake
Journal:  Acta Physiol (Oxf)       Date:  2014-09-27       Impact factor: 6.311

4.  Localized contractions in the normal human bladder and in urinary urgency.

Authors:  Marcus J Drake; Ian J Harvey; James I Gillespie; Wim A Van Duyl
Journal:  BJU Int       Date:  2005-05       Impact factor: 5.588

5.  Specificity evaluation of antibodies against human β3-adrenoceptors.

Authors:  Hana Cernecka; Peter Ochodnicky; Wouter H Lamers; Martin C Michel
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2012-06-12       Impact factor: 3.000

6.  Efficacy and Safety of Mirabegron Add-on Therapy to Solifenacin in Incontinent Overactive Bladder Patients with an Inadequate Response to Initial 4-Week Solifenacin Monotherapy: A Randomised Double-blind Multicentre Phase 3B Study (BESIDE).

Authors:  Marcus J Drake; Christopher Chapple; Ahmet A Esen; Stavros Athanasiou; Javier Cambronero; David Mitcheson; Sender Herschorn; Tahir Saleem; Moses Huang; Emad Siddiqui; Matthias Stölzel; Claire Herholdt; Scott MacDiarmid
Journal:  Eur Urol       Date:  2016-03-08       Impact factor: 20.096

7.  Effect of (R)-2-(2-aminothiazol-4-yl)-4'-{2-[(2-hydroxy-2-phenylethyl)amino]ethyl} acetanilide (YM178), a novel selective beta3-adrenoceptor agonist, on bladder function.

Authors:  Toshiyuki Takasu; Masashi Ukai; Shuichi Sato; Tetsuo Matsui; Itsuro Nagase; Tatsuya Maruyama; Masao Sasamata; Keiji Miyata; Hisashi Uchida; Osamu Yamaguchi
Journal:  J Pharmacol Exp Ther       Date:  2007-02-09       Impact factor: 4.030

8.  β-Adrenergic receptor subtype expression in myocyte and non-myocyte cells in human female bladder.

Authors:  Brian J Limberg; Karl-Erik Andersson; F Aura Kullmann; Glenna Burmer; William C de Groat; Jan S Rosenbaum
Journal:  Cell Tissue Res       Date:  2010-10-16       Impact factor: 5.249

9.  Effects of mirabegron, a novel β3-adrenoceptor agonist, on primary bladder afferent activity and bladder microcontractions in rats compared with the effects of oxybutynin.

Authors:  Naoki Aizawa; Yukio Homma; Yasuhiko Igawa
Journal:  Eur Urol       Date:  2012-09-05       Impact factor: 20.096

10.  Modulation of nerve-evoked contractions by β3-adrenoceptor agonism in human and rat isolated urinary bladder.

Authors:  Céline Rouget; Moèz Rekik; Philippe Camparo; Henry Botto; Pascal Rischmann; Philippe Lluel; Stefano Palea; Timothy D Westfall
Journal:  Pharmacol Res       Date:  2013-12-28       Impact factor: 7.658
  10 in total
  3 in total

1.  β3 Adrenoceptor-induced cholinergic inhibition in human and rat urinary bladders involves the exchange protein directly activated by cyclic AMP 1 favoring adenosine release.

Authors:  Isabel Silva; M Teresa Magalhães-Cardoso; Fátima Ferreirinha; Sílvia Moreira; Ana Filipa Costa; Diogo Silva; Cátia Vieira; Miguel Silva-Ramos; Paulo Correia-de-Sá
Journal:  Br J Pharmacol       Date:  2020-02-06       Impact factor: 8.739

2.  β3 Relaxant Effect in Human Bladder Involves Cystathionine γ-Lyase-Derived Urothelial Hydrogen Sulfide.

Authors:  Emma Mitidieri; Annalisa Pecoraro; Erika Esposito; Vincenzo Brancaleone; Carlotta Turnaturi; Luigi Napolitano; Vincenzo Mirone; Ferdinando Fusco; Giuseppe Cirino; Raffaella Sorrentino; Giulia Russo; Annapina Russo; Roberta d'Emmanuele di Villa Bianca
Journal:  Antioxidants (Basel)       Date:  2022-07-28

Review 3.  Pharmacology of the lower urinary tract: update on LUTS treatment.

Authors:  Pedro Abreu-Mendes; João Silva; Francisco Cruz
Journal:  Ther Adv Urol       Date:  2020-05-13
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.